Sheba and Sequentify Join Forces to Enhance Cancer Diagnostics
Sheba Medical Center, a global leader in medical innovation, has joined forces with Sequentify to redefine cancer diagnostics. This groundbreaking collaboration focuses on detecting Clonal Hematopoiesis of Indeterminate Potential (CHIP), a genetic mutation linked to elevated cancer risks and other health complications.
By integrating Sequentify’s InfiniSeq™ Myeloid Malignancies Panel, Sheba aims to accelerate early detection, enabling more effective and personalized treatment strategies.
Dr. Dan Daminissini, Director of the Diagnostic Division at Sheba Medical Center, emphasized the significance of this partnership, stating:
“We are thrilled to partner with Sequentify on this study. As one of Israel’s leading research institutes and hospitals, ranked #9 among the world’s best hospitals by Newsweek, Sheba Medical Center is committed to staying at the forefront of diagnostic innovation. Our ultimate goal is to deliver better, faster, and more cost-effective results to our patients.”
The Importance of CHIP Detection
What Is CHIP?
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to genetic mutations of blood-forming cells within the bone marrow. While not inherently cancerous, CHIP is associated with an increased risk of developing blood cancers such as leukemia, as well as cardiovascular diseases.
These mutations occur as part of the natural aging process but can sometimes be early warning signs of serious health conditions.
Understanding CHIP’s implications is essential for cancer research and treatment. It highlights potential cancer risks and provides critical insights into disease progression, allowing healthcare providers to anticipate complications and adapt treatment strategies accordingly.
Why Early Detection Matters?
Identifying these genetic alterations before symptoms arise allows medical teams to implement proactive monitoring and tailored interventions, potentially preventing the onset of severe illnesses.
For cancer patients, especially those with solid tumors, CHIP detection offers a new avenue for personalized care, ensuring treatments are better aligned with individual genetic profiles.
Advanced Technology at the Core
At the heart of this collaboration is Sequentify’s InfinitSeq™ Myeloid Malignancies Panel, a transformative tool in genomic testing.
Designed to streamline next-generation sequencing (NGS), workflows, InfinitSeq™ significantly accelerates the diagnostic process by reducing sample preparation time to just 3.15 hours.
This speed is complemented by high accuracy and cost-effectiveness, making it an invaluable resource for laboratories seeking to expand their sequencing capabilities without compromising quality.
Sheba’s Role in Pioneering Cancer Care
Ranked among the top 10 hospitals globally by Newsweek, Sheba Medical Center’s Oncology Division, renowned for integrating advanced genomic tools into clinical practice, exemplifies Sheba’s leadership in cancer diagnostics and treatment.
By adopting technologies like InfinitSeq™, Sheba enhances its diagnostic capabilities, but also sets a new standard in personalized oncology care. This approach ensures patients receive tailored treatments informed by the latest advancements, aligning with Sheba’s mission to transform global healthcare and improve outcomes for all.
A Collaborative Research Initiative
This groundbreaking study represents a powerful collaboration between Sheba Medical Center, Maccabi Healthcare Services, and Sequentify. Together, these leading institutions aim to redefine cancer care through a focused exploration of CHIP.
By leveraging Sequentify’s Panel, the study seeks to redefine personalized medicine approaches and establish new care protocols that could shape the future of oncology treatment.
Redefining Cancer Treatment Worldwide
This initiative underscores the scalability of genomic solutions like Sequentify’s InfiniSeq™ Panel, which can be adapted to healthcare systems worldwide. By reducing costs and turnaround times, this technology paves the way for broader accessibility, particularly in resource-limited settings.
This partnership also inspires global initiatives by demonstrating the value of shared expertise and resources. Institutions worldwide can replicate this model to foster advancements in diagnostics, treatment, and research, ultimately improving healthcare outcomes on a global scale.
More Posts
Twinning and Training: Scalable Solutions for Global Eye Cancer Equity
Sheba Global Ophthalmology (SGO) demonstrates how sustainable twinning and hands-on training create self-reliant ocular oncology capacity in low- and middle-income countries (LMICs), far surpassing the limitations of short-term outreach.
ARC Launches HaMeirim: Sheba’s New Cardiovascular Innovation Center
Sheba Medical Center’s ARC innovation arm has launched and inaugurated HaMeirim – ARC Cardiovascular (“The Radiant Ones” or “Those who shine”), a dedicated innovation center for the Heart, Thorax, and Vascular Center.
Understanding HIV, AIDS, and Prevention with Professor Itsik Levi
In a new “Doctor on Call” video, Professor Itsik Levi, director of the HIV and STDs clinic at Sheba Medical Center, addresses common questions about HIV and AIDS and highlights why early testing is so important. He explains that being HIV-positive means living with the virus, while AIDS refers to a stage of severe immune system damage in which the body can no longer fight off everyday infections.
